AJ 099
Alternative Names: AJ-099Latest Information Update: 12 Dec 2025
At a glance
- Originator A&J Science
- Class Antibacterials; Antituberculars; Peptide antibiotics; Skin disorder therapies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mycobacterial infections; Mycobacterium avium complex infections; Nontuberculous mycobacterium infections; Pseudomonal infections; Staphylococcal infections
Most Recent Events
- 24 Nov 2025 Preclinical trials in Mycobacterial infections in South Korea (Inhalation) prior to November 2025 (A&J Science pipeline, November 2025)
- 24 Nov 2025 Preclinical trials in Mycobacterium avium complex infections in South Korea (Inhalation) prior to November 2025 (A&J Science pipeline, November 2025)
- 24 Nov 2025 Preclinical trials in Nontuberculous mycobacterium infections in South Korea (Inhalation) prior to November 2025 (A&J Science pipeline, November 2025)